Immunovant says Phase 3 batoclimab trials miss primary endpoint in thyroid eye disease

Immunovant Inc +1.59%
Roivant Sciences Ltd. -1.59%

Immunovant Inc

IMVT

24.89

+1.59%

Roivant Sciences Ltd.

ROIV

27.88

-1.59%

  • Immunovant reported topline results from two Phase 3 studies of batoclimab in thyroid eye disease, with results already presented in this update.
  • Both trials missed primary endpoint, raising uncertainty around batoclimab commercial prospects in thyroid eye disease.
  • Safety profile matched prior studies, with no new safety signals flagged.
  • Immunovant shifted emphasis to IMVT-1402 development across autoimmune diseases, with Graves’ disease positioned as key priority.
  • Topline data from potentially registrational IMVT-1402 studies in Graves’ disease expected in calendar year 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunovant Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604020500PRIMZONEFULLFEED9683237) on April 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.